AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Study Number

2962822

Phase

Age Group

Adult

Principal Investigator

Purpose

This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.

Check your eligibility for this trial

Check now

Full Title

AB-1015-101: AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AB-1015 IN PATIENTS WITH PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER

ClinicalTrials.Gov ID

NCT05617755

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.